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Dietary proteins play an important role in the regulation of systemic immune response, in a phenomenon
known as oral tolerance (OT). To evaluate the effects of OT on a murine model of type II collagen (CII) plus
ovalbumin (OVA)-induced arthritis (CIA), mice were fed with OVA either before or after CIA induction. OT
signiﬁcantly reduced the paw edema and synovial inﬂammation, as well as serum levels of anti-CII, the
ex vivo proliferation and inﬂammatory cytokine production by spleen cells from CIA mice. The frequen-
cies of Foxp3+ and IL-10+ cells were higher, whereas IFNc+ cells and IL-17+ cells were lower, among gated
CD4+ spleen T cells from tolerized CIA mice than in those from non-tolerized CIA mice. Adoptive transfer
of tolerogenic dendritic cells (DCs) before CIA induction mimics the effects observed in the OT. We dem-
onstrate here that bystander suppression induced by OT can modify the course of CIA and tolerogenic DCs
play a role this phenomenon.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Human rheumatoid arthritis is a chronic inﬂammatory autoim-
mune disease characterized by pain, swelling and deformity of the
joints. The immune response in arthritis involves the activation of
antigen-speciﬁc lymphocytes secreting inﬂammatory cytokines
that act on macrophages, osteoclasts and cells adjacent to inﬂamed
synovial tissue [1]. Collagen-induced arthritis (CIA) is the most
studied experimental model of rheumatoid arthritis, which
involves the administration type II collagen (CII) plus complete
Freund’s adjuvant (CFA) in susceptible strains of mice and rats. In
resistant BALB/c mice, however, CIA is only observed when a sec-
ond protein, such as keyhole-limpet hemocyanin (KLH) or ovalbu-
min (OVA), is combined to the CII and CFA [2].
The use of knockout animals and blockage with monoclonal
antibodies has shown that IL-17, IFN-c and TNF-a play a funda-
mental role in the establishment of arthritis [3–5]. Monoclonal
antibody based therapies have been proved to be an alternative
to the classic use of immunosuppressive disease-modifying anti-
rheumatic drugs [6], with rare adverse effects in humans [7,8].sevier OA license. 
mé), lgrf1982@yahoo.com.br
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eiro), wirlatam@unicamp.brOral tolerance (OT) has been successfully used to alter the
course of inﬂammatory responses in some experimental autoim-
mune diseases [9,10]. Joint inﬂammation, for example, has been
signiﬁcantly reduced in mice tolerized by repeated oral feeding
of CII before CIA induction [9]. The tolerized mice also exhibited
an increased serum IgG1, a reduction of serum IgG2a, a suppres-
sion of speciﬁc proliferative response of T cells from lymph nodes,
and an increased frequency of cells producing IL-10 amongst T
CD4+CD25+ splenic cells stimulated with CII.
Dendritic cells (DCs) play an important role in immune
responses of T lymphocytes that occur in the microenvironment
of digestive tract mucosa, directing them to either an effector
proﬁle or systemic tolerance to the antigen. The main effect in-
duced by DCs in immune tolerance seems to be the expansion of
TGF-b- and IL-10-secreting regulatory T lymphocytes (Tregs) that
inhibit the development of IFN-c-, TNF-a- and IL-17-secreting T
cells [9–11]. CD103+ DCs in small intestine exhibit an enhanced
ability to metabolize vitamin A and generate its major active
metabolite retinoic acid [12]. It has been suggested that retinoic
acid underlies the CD103+DC capacity to induce the gut homing
receptors CC chemokine receptor (CCR)9 and a4b7 on responding
T and B cells, to enhance transforming growth factor
(TGF)b-dependent naïve T cell conversion to forkhead box (Fox)P3+
T regulatory cells (Tregs) while suppressing TGFb-dependent Th17
cell differentiation [13,14].
However, currently it is unknown whether OT to ovalbumin is
capable of reducing clinical signs of CIA in BALB/c mice. In this
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the severity of CIA in BALB/c mice, and that this phenomenon oc-
curred when OVA is administered either before or after the onset
of the disease. Our data also suggested that bystander suppression
induced by the ingestion of OVA leads to the generation of
tolerogenic DCs with the consequent increase of the proportion
of CD25+Foxp3+ Tregs and secretion of anti-inﬂammatory cyto-
kines in arthritic mice.
2. Material and methods
2.1. Animals
Eight weeks old male BALB/c mice from the Multidisciplinary
Center for Biological Research, University of Campinas (UNICAMP),
were used in this study. The animals were kept in speciﬁc-pathogen
free condition, in a controlled temperature and photoperiod envi-
ronment, with autoclaved food and water ad libitum throughout
the experiment. The protocols involving laboratory animals were
approved by the Institutional Committee (Comissão de Ética no
Uso de Animais – CEUA/UNICAMP; Protocol number 1759-1).
2.2. Oral tolerance
The induction of OT to OVA followed the protocol previously de-
scribed [15]. Brieﬂy, 4 mg/mL OVA (Sigma–Aldrich, St. Louis, MO,
USA) were added to water supply, for a week. After this period,
the liquid supply was replaced by protein-free water. Three ani-
mals in this group were challenged with two doses of 10 lg OVA
plus 1 mg AlOH3 at intervals of 1 week to evaluate the induction
of OT. Low levels of anti-OVA detected in sera obtained from these
animals indicated the success of the procedure adopted.
2.3. Type II collagen-induced arthritis
Arthritis was induced in male mice as described elsewhere [2].
Brieﬂy, chicken type II collagen (kindly provided by Dr. Benedito
dos Campos Vidal, UNICAMP) and OVA were emulsiﬁed in com-
plete Freund’s adjuvant (CFA). Animal of naïve group received a
subcutaneous (s.c.) dose of antigens constituted by mixture of
100 lg of each protein emulsiﬁed in CFA (v:v) at the base of the
tail. Two additional doses of the CII + OVA in CFA were applied
on days 21 and 45. Half of this group of mice was fed with OVA
to induce tolerance over the days 28 and 35 after the beginning
of subcutaneous immunization. A third group consisted of male
mice fed OVA for 7 consecutive days prior arthritis induction. On
day 65, mice of all groups were euthanized for histological and
immunological analysis.
2.4. Evaluation of inﬂammation and histological analysis
In order to evaluate the articular edema in CIA mice, paw thick-
nesses were measured weekly from day 21 to 65. On day 65 after
CIA induction, the animals of each experimental group were sacri-
ﬁced, its hind legs were dissected, ﬁxed and decalciﬁed in formic
acid solution 15% and formaldehyde 5%, cut in microtome (cuts
of 6 lm) and stained in Sirius Red for histopathological
examination.
2.5. Detection of serum antibodies
Detection of anti-OVA serum antibodies was carried out in
microtiter plates covered with 20 lg/mL OVA in sodium carbonate
buffer, pH 9.0, as described elsewhere [15]. To detect anti-type II
collagen serum antibodies, plates were covered with 20 lg/mLchicken type II collagen (Chondrex Inc, Redmond, WA, USA) in
phosphate buffered saline (PBS) pH 7.2 as described elsewhere
[16]. Absorbance was read at 492 nm in an ELISA reader (Labsys-
tem MS, Finland). The results of ELISA were expressed as averages
of sum ± standard error of mean (S.E.M.) of the optical densities ob-
tained in each experimental group.
2.6. Co-culture experiments
Dendritic cells were isolated from spleens of naïve, immunized
and OVA-tolerant mice employing anti-CD11c magnetic beads
(Miltenyi Biotech, Auburn, CA, USA) following the manufacturer’s
recommendations. After puriﬁcation procedures, about 80% of the
cells were MHC II+ and only 3% were CD3+. CD11c+ DCs at concen-
tration of 1  106cells/mL were pulsed for 18 h with 50 lg/ml of
CII. Splenic cells from arthritic mice were enriched in T lympho-
cytes using nylon wool column, according to protocol previously
described [15]. T lymphocytes were stained with carboxyﬂuores-
cein succinimidyl ester (CFSE) according to manufacturer’s recom-
mendations (Sigma), and cultured in 96-well plates at a
concentration of 2  105/well in the presence of pulsed DCs at a
ratio of 10:1 (T:DC) with 50 lg/ml CII for 96 h. Before the addition
of antigen, an aliquot of stained cells was withdrawn for analysis
by ﬂow cytometer to deﬁne the maximum value of incorporation
of the probe. Supernatants were collected for dosage of cytokines
through ELISA. To measure proliferation, cells were ﬁxed with
PBS containing 1% formaldehyde, transferred to appropriate tubes
and analyzed in ﬂow cytometer. To examine expansion of subsets
of T lymphocytes, aliquots were processed to ﬂow cytometry.
2.7. Measurement of cytokines
At the end of the lymphocyte cultures, the supernatants were
collected for dosage of cytokines through ELISA, using commercial
kits according to manufacturer’s recommendations. It was ana-
lyzed: IL-12, TNF-a (BD PharMingen), IL-17, IL-6, IFNc, IL-10, IL-4
and TGF-b (e-Bioscience).
2.8. Adoptive transfer experiments
2.8.1. Dendritic cell puriﬁcation and transfer
Splenic dendritic cells were isolated from naïve and OVA-toler-
ant mice employing anti-CD11c magnetic beads (Miltenyi Biotech),
according to the manufacturer’s recommendations. Cells were
pulsed with OVA 50 lg/mL during 18 h and adoptively transferred
to naïve mice via retro-orbital plexus, in three doses of 5  105 cells
per animal on days 6, 4 and 2 before the CIA induction.
2.8.2. Spleen cell proliferation
On day 65 after CIA induction, mice of all groups of the adoptive
transfer experiments were killed and spleens were aseptically
removed. Splenocytes were stained with CFSE, seeded at 2  105
cells/well in the presence of 50 lg/mL CII, and then incubated for
96 h at 37 C in humidiﬁed incubator with CO2 5%. Cells cultured
in absence of stimuli were used as baseline control. Supernatants
were collected for dosage of cytokines. The cells were ﬁxed with
PBS containing 1% formaldehyde and proliferation was assessed
in CD3+CFSElow by ﬂow cytometry. The results were expressed as
proliferation index (fold change), calculated by dividing the per-
centages found in the experimental groups by the percentage
found in the control group.
2.9. Flow cytometry
Following cultivation or in vivo treatments, single cell suspen-
sions were washed and suspended in staining buffer (PBS plus
Fig. 1. Oral administration of OVA suppresses CIA in BALB/c mice. OVA solution (4 mg/mL) was offered in drink water to male BALB/c mice (n = 5) for 7 consecutive days,
either before or after (at 28 days after the ﬁrst dose of antigens) of the beginning of subcutaneous (sc) injections to induce CIA. Arthritis was induced by immunization with
OVA + CII (100 lg of each antigen) emulsiﬁed with CFA, via s.c., administered at day 1, 21, and 45. (A) The thickness of the paws was taken every 3 days, since day 21 until the
time of sacriﬁce. (B) Hind paws were dissected, embedded in parafﬁn and processed for histological analysis by Sirius red. (C, D) Sera were diluted from 1:100 to 1:1280 and
tested in reactions of ELISA for detection of anti-CII and anti-OVA antibodies, respectively. Values are mean O.D. sums ± S.E.M. (n = 6). Data are representative of three
independent experiments. Two-way ANOVA followed by Bonferroni’s post-test were used to determine statistical signiﬁcance in mean paw thickness in comparison to CIA
group; ⁄P 6 0.05. One-way ANOVAwas used to determine statistical signiﬁcance in mean O.D. sums; ⁄P 6 0.05 in comparison to naïve mice and #P 6 0.05 in comparison to CIA
group. (For interpretation of color in Figs. 1 and 5, the reader is referred to the web version of this article.)
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with anti-CD3-PerCP-Cy5.5, anti-CD4-PECy7, anti-CD25-PE and
their respective isotype controls for 30 min at 4 C. Next, cells were
incubated with ﬁxation/permeabilization buffer for 30 min and
probed for intracellular cytokines using anti-Foxp3-APC,anti-IL-17-APC or -PE, anti-IFN-c-APC or -PE and anti-IL-10-PE
and their respective isotype controls. All FACS reagents were pur-
chased from eBiosciense (San Diego, CA, USA) and used following
manufacture’s recommendation. Preparations were acquired in
FACS Aria ﬂow cytometer (BD Becton Dickinson, San Jose, CA,
Fig. 2. Suppression of collagen-speciﬁc proliferation of T lymphocytes, increased proportion of CD25+Foxp3+ Tregs and IL-10-producing-T cells after oral administration of
ovalbumin. BALB/c mice were fed with OVA, either before or after CIA induction by subcutaneous immunization with OVA + CII/CFA. Leukocytes were harvested from spleens
60 days after the primary immunization, and suspensions were stained with CFSE and cultured (2  105 cells/well) for 96 h in the presence of 50 lg/mL CII. (A) T cell
proliferation was determined using ﬂow cytometry and assessed by ﬂuorescence decay of the probe in the gate of CD3+ cells. IL-10-, IFNc- and IL-17-producing cells were
evaluated in the gate of CD3+CD4+ cells. (B) The frequency of CD4+CD25+ Foxp3+ T lymphocytes was evaluated in the gate of CD3+CD4+ cells. Data in %bar graphs represent the
mean ± S.E.M. (n = 4) of cell frequencies obtained in three independent experiments and histograms are derived from a representative experiment. One-way ANOVA followed
by Bonferroni’s post-test were used to determine statistical signiﬁcances; P 6 0.05 in comparison with naïve (⁄) and CIA (#) groups.
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Star Inc., Ashland, OR, USA).2.10. Statistical analysis
The results were analyzed by one-way ANOVA or two-way AN-
OVA followed by Bonferroni’s post-test, determining as statistically
signiﬁcant the differences with values of P 6 0.05. For the purposes
of drafting this analysis, we used the GraphPad Prism5 Software.3. Results
3.1. Intake of ovalbumin modulates experimental arthritis
BALB/c mice immunized with CII + OVA/CFA developed arthritis
characterized by inﬂammatory reaction in joints, with the increase
of paw thickness and histological changes in synovial cartilages, as
illustrated in Fig. 1. Intake of OVA either before or after CIA induc-
tion led to a signiﬁcant decrease in paw edema and in the inﬂam-
matory reaction in joints (Fig. 1A). The most signiﬁcant histological
Fig. 3. Changes induced by OT to ovalbumin on cytokine production in cultures of splenic cells from CIA mice re-stimulated with CII. Leukocytes from spleens of CIA mice
submitted or not to the protocol for OT with OVA were harvested 60 days after the primary immunization. Cell suspensions were cultured (2  105 cells/well) for 96 h in the
presence of 50 lg/mL CII. Cells from naïve mice were used as a control. Culture supernatants were collected for dosage of IL-10, IL-4, TGFb, IL-12p40, IFNc, IL-17, IL-6 and
TNFa (A–H, respectively) using commercial ELISA kits, according to manufacturer’s indications (e-Bioscience). Data are representative of two independent experiments. One-
way ANOVA followed by Bonferroni’s post-test were used to determine statistical signiﬁcances; P 6 0.05 in comparison with naïve (⁄) and CIA (#) groups.
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deposition in the synovia of nontolerized CIA mice in comparison
with tolerized group (Fig. 1B). Anti-CII and anti-OVA levels were
also signiﬁcantly more reduced in sera of tolerized group than in
the nontolerized CIA mice (Fig. 1C and D, respectively).
We then investigated the proliferation of spleen cells under
in vitro stimulation with CII. As depicted in Fig. 2, proliferation of
T lymphocytes from CIA mice fed with OVA either before or after
CIA induction was signiﬁcantly lower than in CIA control group
(Fig. 2A), while the frequency of CD25+Foxp3+ Tregs cells increased
in those cultures (Fig. 2B). We also observed an increased fre-
quency of IL10+CD4+ T cells in the cultures of spleen cells from
mice fed with OVA, as well as a reduction of the frequencies of
IL17+CD4+ and IFN-c+CD4+ T cells, as compared with the CIA group(Fig. 2A). The levels of IL-10, IL-4 and TGF-b were higher in culture
supernatants of spleen cells from tolerized mice than in CIA mice
(Fig. 3A–C), whereas IL-12, IFN-c, IL-6, IL-17 and TNF-a were more
reduced in those cultures (Fig. 3C and E–H).
3.2. Tolerogenic dendritic cells favor immuneregulation
We next aimed to evaluate the effect of dendritic cells from tol-
erant mice on immune functions of lymphocytes from CIA mice.
CD11c+ DCs were puriﬁed from spleens of OVA-tolerant mice and
co-cultured with spleen lymphocytes of CIA mice in the presence
of CII. DCs isolated from naïve and OVA-immunized mice were
used as controls. As depicted in Fig. 4, the antigen-speciﬁc prolifer-
ation of lymphocytes from CIA mice was signiﬁcantly higher when
Fig. 4. Dendritic cells from tolerized mice suppress collagen-speciﬁc proliferation, increase proportion of CD25+Foxp3+ Tregs and change cytokine proﬁle in co-cultures with
spleen cells from CIA mice. CD11c+ cells were isolated from spleens of naïve (DCn), immunized (DCip) and tolerant (DCo) mice using magnetic beads coated with a-CD11c
antibodies, and then pulsed with CII (50 lg/mL) for 18 h. Leukocytes from spleens of CIA mice were harvested 60 days after the primary immunization, enriched in T
lymphocytes by passage in nylon wool columns, and stained with CFSE. Spleen lymphocytes (2  105 cells/well) were cultured for 96 h in the presence of 2  104 pulsed DCs
and 50 lg/mL CII. (A and B) T cell proliferation was determined using ﬂow cytometry and assessed by ﬂuorescence decay of the probe in the gate of CD3+ cells. (A and C) The
frequency of CD25+ Foxp3+ T lymphocytes was evaluated in the gate of CD3+CD4+ cells. (D–K) Cytokines IL-10, TGFb, IL-4, IL-12, IL-17, IFNc, IL-6 and TNF-a were detected in
the culture supernatants by ELISA. Data in bar graphs represent the mean ± S.E.M. (n = 6) of cell frequencies and cytokine production obtained in three independent
experiments. One-way ANOVA followed by Bonferroni’s post-test were used to determine statistical signiﬁcances; P 6 0.05 in comparison with naïve (⁄) and CIA (#) groups.
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and B). The analysis of lymphocyte subpopulations present in cul-
tures shows that there was a signiﬁcant increase in the proportion
of CD25+Foxp3+Treg cells when T lymphocytes were grown in the
presence of tolerogenic DCs (Fig. 4A and C). The secretion of IFN-c
and IL-12 was higher in co-cultures carried out in the presence of
DCs from OVA-immunized mice than DCs from tolerant mice
(Fig. 4I and G, respectively). On the other hand, the amounts of
IL-10 and IL-4 were signiﬁcantly higher in cultures conducted in
the presence of DCs from tolerized mice (Fig. 4D and F, respec-
tively). The secretion of IL-6 was signiﬁcantly lower in cultures
conducted in the presence of DCs from tolerant mice in comparisonwith those carried out with DCs from immunized mice (Fig. 4J). No
signiﬁcant differences were found in secretion of IL-17, TNF-a, and
TGF-b in cultures carried out with naïve or arthritic mouse lym-
phocytes and DCs from naïve, tolerant or immune mice (Fig. 4H,
K and E, respectively).
3.3. The adoptive transfer of tolerogenic dendritic cells modulates CIA
To examine the possibility of controlling the signs of the dis-
ease, we performed experiments of passive transfer of splenic
DCs from either naïve or tolerant mice before inducing CIA in male
mice. The passive transfer of tolerant CD11c+DCs resulted in
Fig. 5. Adoptive transfer of tolerogenic dendritic cells suppresses CIA in BALB/c mice. CD11c+ DCs were isolated from spleens of naïve (DCn) and OVA-tolerized(DCo) mice and
then adoptively transferred to male mice (n = 5, three injections of 5  105 DCs/mouse) before the administration of CII + OVA/CFA for induction of CIA. (A) Paw thickness was
taken every 3 days after the ﬁrst immunization until the end of the experiment. (B) At day 60, mice were euthanized and hind paws were dissected, embedded in parafﬁn and
processed for histological analysis in Sirius red. (C and D) Sera were diluted from 1:100 to 1:1280 and tested in reactions of ELISA for detection of anti-CII and anti-OVA
antibodies, respectively. Values are mean O.D. sums ± S.E.M. (n = 6). Data are representative of three independent experiments. Two-way ANOVA followed by Bonferroni’s
post-test were used to determine statistical signiﬁcance in mean paw thickness in comparison to CIA group; ⁄P 6 0.05. One-way ANOVA was used to determine statistical
signiﬁcance in mean O.D. sums; ⁄P 6 0.05 in comparison to naïve mice and #P 6 0.05 in comparison to CIA group.
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Fig. 6. Adoptive transfer of tolerogenic DCs reduces the collagen-speciﬁc proliferation of T lymphocytes, increase the proportion of CD25+Foxp3+Tregs and IL-10- producing-T
cells. Sixty days after the ﬁrst immunization to induce CIA, leukocytes were harvested from spleens of mice that previously received CD11c+ DCs isolated from naïve (DCn)
and tolerized (DCo) mice. Leukocytes from spleens of naïve and untreated CIA mice were used as controls. The spleen cells were stained with CFSE and cultured for 96 h in the
presence of CII (50 lg/mL). (A) T cell proliferation was determined using ﬂow cytometry and assessed by ﬂuorescence decay of the probe in the gate of CD3+ cells. IL-10-,
IFNc- and IL-17-producing cells were evaluated in the gate of CD3+CD4+ cells as well. (B) The frequency of CD25+ Foxp3+ Tregs in the different groups was evaluated in the
gate of CD3+CD4+ cells. Data in %bar graphs represent the mean ± S.E.M. (n = 4) of cell frequencies obtained in two independent experiments and histograms are derived from
a representative experiment. One-way ANOVA followed by Bonferroni’s post-test were used to determine statistical signiﬁcances; P 6 0.05 in comparison with naïve (⁄) and
CIA (#) groups.
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synovial cartilage changes in CIA mice (Fig. 5B), but the levels of
anti-CII and anti-OVA antibodies in sera of CIA mice were not mod-
iﬁed by the adoptive transfer of any DCs (Fig. 5C and D, respec-
tively). CII-induced proliferation was lower in T cell cultures
from recipients of tolerogenic DCs than in cultures of the control
groups (Fig. 6A). The frequency of IFN-c- and IL-17-producing
CD4+ cells was signiﬁcantly reduced in cultures of spleen cells from
recipients of either naïve or tolerogenic DCs in comparison to con-
trol CIA group, whereas the frequency of IL-10-producing cells wassigniﬁcantly higher in those cultures (Fig. 6A). On the other hand,
the frequency of CD25+Foxp3+ Tregs was higher in T cell cultures
from recipients of either naïve or tolerogenic DCs than in the con-
trol groups (Fig. 6B). However, the levels of IL-17 and IFN-c were
signiﬁcantly higher in supernatants of cultures of spleen cells from
recipients of naïve DCs in comparison to those of the CIA control
group (Fig. 7E and F, respectively), whereas the levels of TGF-b
were signiﬁcantly higher in cultures of spleen cells from recipients
of tolerogenic DCs than in all other groups (Fig. 7C). The amounts of
IL-6 and TNF-a were lower in the culture supernatants of spleen
Fig. 7. Adoptive transfer of tolerogenic dendritic cells alters cytokine production in splenic cells from CIA mice re-stimulated in vitro. Sixty days after the ﬁrst immunization
to induce CIA, leukocytes were harvested from spleens of mice that previously received CD11c+ DCs isolated from naïve (DCn) and tolerized (DCo) mice. Leukocytes from
spleens of naïve and untreated CIA mice were used as controls. The spleen cells were cultured for 96 h in the presence of CII (50 lg/mL). (A–H) Cytokines IL-10, IL-4, TGFb, IL-
12p40, IFNc, IL-17, IL-6 and TNF-awere detected in the culture supernatants by ELISA. Data in bar graphs represent the mean ± S.E.M. (n = 6) of cytokine production obtained
in three independent experiments. One-way ANOVA followed by Bonferroni’s post-test were used to determine statistical signiﬁcances; P 6 0.05 in comparison with naïve (⁄)
and CIA (#) groups.
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control group (Fig. 7G and H, respectively). On the other hand, the
levels of IL-10, IL-4, and IL-12 were higher in the culture superna-
tants of spleen cells from recipients of any kind of DCs in compar-
ison to those observed in cultures of spleen cells from either naïve
or CIA mice (Fig. 7A, B and D, respectively).4. Discussion
In this study, we show that CIA induced in BALB/c mice through
the administration of OVA + CII in CFA can be both prevented andtreated by OVA ingestion. We observed that OT to OVA led to an
increase of CD25+Foxp3+Tregs and IL10-producing T lymphocytes
in spleens of arthritic mice, with diminished production of IL-6,
TNF-a and IFN-c by spleen cells. We also found that transfer of
splenic dendritic cells from OVA-tolerized mice was able to reduce
the severity of arthritis through the induction of CII-speciﬁc Tregs.
To our knowledge this is the ﬁrst time that it is shown a reduction
of the inﬂammatory response in experimental arthritis by transfer-
ring DCs pulsed with CII-unrelated antigen.
Arthritis induced by collagen is the most studied and character-
ized experimental model of rheumatoid arthritis, because the af-
fected animals show similar clinical and immunological signs to
122 R. Thomé et al. / Cellular Immunology 280 (2012) 113–123those observed in human disease [17]. The genetic background of
animals as well as in humans exerts great inﬂuence on the develop-
ment of the disease. Mice of H-2q and H-2r haplotypes, such as DBA
1 and B10q, are more susceptible to CIA [18]. It has been shown,
however, that BALB/c mice (H-2d) develop CIA when an exogenous
protein, such as KLH and OVA, is included in the antigen prepara-
tion together with bovine type II collagen [2]. Similarly to describe
in other studies [19,20], we observed that BALB/c mice immunized
with chicken type II collagen plus OVA in CFA showed clinical man-
ifestations typical of arthritis, such as the cartilage erosion caused
by chondrocyte hyperplasia and increased deposition of collagen
in the zone of hyaline cartilage, leading to intensiﬁcation of the cal-
ciﬁcation process in the more advanced stages of the disease. How-
ever, in contrast to that observed by Backstrom and Dahlgren [2],
our data show an expressive proliferation of spleen T cell from
CIA mice following in vitro re-stimulation with CII.
The manipulation of speciﬁc immune responses has been the
subject of intense study, aiming at developing anti-inﬂammatory
therapy alternatives to the use of nonspeciﬁc immunosuppressive
drugs of broad-spectrum [21]. In this sense, the oral route of toler-
ance induction has been exploited in studies on the control of aller-
gic [22] and autoimmune reactions [23], as well as experimental
treatment of transplants [24]. In our study, we show that the con-
sumption of OVA by a 7-day period, either before or after the paren-
teral immunization, signiﬁcantly reduced the severity of CIA, as
observed by reduction of paw edema in tolerized CIA animals. We
also observed that the structures and arrangement of synovial carti-
lageswere preserved in tolerizedmicewhen compared to untreated
CIA mice. The most relevant immunological parameters exhibited
by OVA-tolerized CIA mice were the reduction of the levels of
anti-CII antibodies, reduction of antigen-speciﬁc proliferation, in-
crease of Treg and elevation of the anti-inﬂammatory cytokines
TGF-b and IL10. Likewise, it was reported in the literature that the
consumption of OVA reduced the immunological parameters of
arthritis in DBA/1 mice, although the clinical signs were not signiﬁ-
cantly altered [25]. On the other hand, collagen-induced OT
suppressed inﬂammation in arthritic DBA-1 mice trough the
expansion of IL-10-producing CD4+CD25+ T cells. The same pattern
of suppression was recently described in experimental lung trans-
plantation preceded by oral administration of type V collagen [24].
In this case, the survival of transplantwas also associated to immune
responses involving expansion of Treg cells secreting IL-10 and
TGFb. Our data, however, show that OT to OVA can improve exper-
imental arthritis in BALB/c mice as a consequence of the downregu-
lation of both humoral and cellular immune responses to CII in a
nonspeciﬁc fashion, through the increase of CD25+Foxp3+ and
CD4+IL-10+ T cell subsets as demonstrated by in vitro re-stimulation
with CII.
Dendritic cells play a fundamental role in the establishment of
the peripheral tolerance [26,27]. Corroborating the literature data,
our results show that DCs from tolerant mice are able to modulate
the proliferation of T lymphocytes of arthritic mice and induce an
increase in the frequency of CII-speciﬁc Treg amongst splenic cells
stimulated in vitro with collagen. Based on these ﬁndings, we
sought to evaluate whether adoptive transfer of DCs from OVA-
tolerant mice could alter the course of CIA in BALB/c mice. Spleen
cells from arthritic mice adoptively transferred with DCs from
either naïve or tolerant mice showed increased levels of IL-10
and IL-4 and reduced levels of TNF-a and IL-6, following re-
exposition to CII in vitro. On the other hand, IFN-c and IL-17 were
down-regulated in cells from mice adoptively transferred with
either naïve or tolerogenic DCs, whereas TGF-b was up-regulated
in cells from mice adoptively transferred with tolerogenic DCs. It
was also observed a reduction of proliferative response to CII with
an increase in the frequency of CD25+Foxp3+ Tregs in the cultures
of spleen cells from recipients of tolerogenic DCs. These cytokineand cellular proﬁles seem to correlate with the severest cartilage
alterations observed in animals that received naïve DCs in compar-
ison to those treated with tolerogenic DCs. The literature provides
some examples of improvements in experimental arthritis with
tolerogenic DCs. In this sense, adoptive transfer of DCs modulated
with CTLA-4-Ig, which make them tolerogenic cells, was capable of
promoting the improvement of the clinical picture of CIA induced
in DBA/1J by expansion of Treg cells [28], as observed in our work.
Likewise, CD11c+CD11b+DCs isolated from Peyer patches of toler-
ized DBA-1 mice also confer protection against CIA [29].5. Conclusions
Taken together, our results indicate that bystander suppression
following OVA consumption is able to reduce the severity of clini-
cal manifestations of experimental arthritis, an effect mimicked by
adoptive transfer of DCs obtained from tolerized mice. Tolerogenic
DCs, in turn, are able to induce the proliferation of antigen-speciﬁc
regulatory T cells, with potential to suppress the response of path-
ogenic T lymphocytes, improving the clinical signs of experimental
arthritis. Further studies, however, are necessary to evaluate the
applicability of these procedures in other autoimmune manifesta-
tions and eventually in human patients.Funding
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